US Stock Futures Edge Lower Ahead Of Earnings - Genpact (NYSE:G), BioLine Rx (NASDAQ:BLRX)

Pre-open movers

US stock futures fell in early pre-market trade. Futures for the Dow Jones Industrial Average tumbled 11 points to 15,927.00, while the Standard & Poor's 500 index futures fell 4 points to 1,784.70. Futures for the Nasdaq 100 index dropped 5.75 points to 3,378.25.

A Peek Into Global Markets

European markets were lower today, with the Spanish Ibex Index tumbling 1.09%, London's FTSE 100 index dropping 0.54% and STOXX Europe 600 Index declining 0.63%. German DAX 30 index fell 0.36% and French CAC 40 Index tumbled 1.03%. Asian markets ended mostly lower today. Japan's Nikkei Stock Average dropped 0.25%, China's Shanghai Composite declined 0.19%, Hong Kong's Hang Seng Index fell 0.01% and India's BSE Sensex jumped 0.19%.

Broker Recommendation

Analysts at Oppenheimer upgraded Mead Johnson Nutrition Company

MJN

from “perform” to “outperform.” The target price for Mead Johnson Nutrition is set to $100. Mead Johnson Nutrition's shares closed at $82.69 yesterday.

Breaking news

ProMetic Life Sciences PFSCF announced today that it has received a $5.1 million purchase order for the supply of affinity resin from an existing client, a global leader in the biotherapeutics industry. To read the full news, click here.
BioLineRx BLRX announced today the publication of results showing that BL-8040 (formerly known as BKT-140) enables the efficient mobilization of stem cells from the bone marrow into the peripheral blood, thus facilitating autologous stem cell transplantation in multiple myeloma patients. To read the full news, click here.
Genpact G today announced a five-year, multimillion dollar services agreement to manage the U.S. IT operations for Credit Agricole CIB (CA-CIB), the Corporate and Investment Banking arm of the Credit Agricole group, the world's fifth-largest bank in total assets and Europe's fourth-largest bank by Tier one equity. To read the full news, click here.
Nektar Therapeutics NKTR reported today that partner AstraZeneca announced that the United States Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for naloxegol, an investigational peripherally-acting mu-opioid receptor antagonist (PAMORA), which has been studied in opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, the most common side effect caused by chronic administration of prescription opioid pain medicines. To read the full news, click here.

Market News and Data brought to you by Benzinga APIs